Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P42345 (
mTOR
)
26,049
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Activation of axonal growth program is a critical step in successful optic nerve regeneration following injury. Yet the molecular mechanisms that orchestrate this developmental transition are not fully understood. Here we identified a novel regulator,
insulin-like growth factor binding protein-like 1
(
IGFBPL1
), for the growth of retinal ganglion cell (RGC) axons. Expression of
IGFBPL1
correlates with RGC axon growth in development, and acute knockdown of
IGFBPL1
with shRNA or
IGFBPL1
knockout in vivo impaired RGC axon growth. In contrast, administration of
IGFBPL1
promoted axon growth. Moreover,
IGFBPL1
bound to insulin-like growth factor 1 (IGF-1) and subsequently induced calcium signaling and
mammalian target of rapamycin
(
mTOR
) phosphorylation to stimulate axon elongation. Blockage of IGF-1 signaling abolished
IGFBPL1
-mediated axon growth, and vice versa, IGF-1 required the presence of
IGFBPL1
to promote RGC axon growth. These data reveal a novel element in the control of RGC axon growth and suggest an unknown signaling loop in the regulation of the pleiotropic functions of IGF-1. They suggest new therapeutic target for promoting optic nerve and axon regeneration and repair of the central nervous system.
...
PMID:IGFBPL1 Regulates Axon Growth through IGF-1-mediated Signaling Cascades. 2939 97